secwatch.observer — SEC 8-K summary
======================================

Issuer:     HARROW, INC. (HROW)
CIK:        0001360214
Form:       8-K
Filed at:   2025-03-27T23:59:59+00:00
Accession:  0001641172-25-000915
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Harrow Q4 revenue $66.8M (+84% YoY), net income $6.8M; FY2025 guidance >$280M
-----------------------------------------------------------------------------

- Q4 revenue $66.8M (+84% YoY); FY2024 revenue $199.6M (+53% YoY).
- GAAP net income Q4 $6.8M vs loss $9.1M; Adjusted EBITDA Q4 $22.5M vs $2.6M.
- IHEEZO unit demand +43% QoQ to 49,130 units; VEVYE prescriptions +44% QoQ, approaching 5% DED market share.
- TRIESENCE awarded CMS transitional pass-through (April 2025-2028); five-year supply agreement with CMO; next-gen NDA by 2027.
- FY2025 revenue guidance 'over $280M' (>40% YoY); cash $47.2M; met leverage ratio, avoided warrant issuance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1360214/000164117225000915/0001641172-25-000915-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1360214/000164117225000915/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-000915

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer